STOCK TITAN

Planned sale of 8,020 HCA (HCA) shares under Rule 144

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A shareholder of HCA Healthcare, Inc. filed a Rule 144 notice to sell 8,020 shares of common stock, with an aggregate market value of 4,126,949.9. The planned sale is through Merrill Lynch on the NYSE, with an approximate sale date of 02/11/2026.

The shares to be sold were acquired via vesting of stock awards from HCA Healthcare, Inc. on 02/17/2023 (5,159 shares), 02/16/2024 (1,680 shares), and 02/13/2025 (1,181 shares), each described as a compensatory payment. The notice also states that the seller represents they do not know any undisclosed material adverse information about HCA’s operations.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for HCA indicate?

The Form 144 indicates a shareholder plans to sell 8,020 HCA Healthcare common shares under Rule 144. The planned transaction has an aggregate market value of 4,126,949.9 and is scheduled for execution on or around 02/11/2026 through Merrill Lynch on the NYSE.

How were the HCA shares in this Form 144 acquired?

The shares were acquired through vesting of stock awards from HCA Healthcare, Inc. Awards vested on 02/17/2023 (5,159 shares), 02/16/2024 (1,680 shares), and 02/13/2025 (1,181 shares), each described as a compensatory payment for the holder.

What is the planned sale method for the HCA shares in this Rule 144 notice?

The notice states the 8,020 common shares are to be sold through Merrill Lynch at its Atlanta, Georgia office. The intended marketplace is the NYSE, with an approximate sale date of 02/11/2026, subject to market conditions and applicable rules.

How many HCA shares are outstanding in this Form 144 disclosure?

The filing reports 228,193,900 HCA common shares outstanding in the class referenced. This figure provides context for the planned sale of 8,020 shares under Rule 144, showing the transaction’s relative size versus the total outstanding shares.

What representation does the seller make in the HCA Form 144?

The seller represents that they do not know any material adverse information about HCA Healthcare’s current or prospective operations that has not been publicly disclosed. This representation is explicitly stated as part of signing the notice required for the planned Rule 144 sale.

Does the HCA Form 144 mention Rule 10b5-1 trading plans?

Yes. The notice explains that if the person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1, by signing they make the same representation as of the plan’s adoption or instruction date, regarding undisclosed material adverse information.
Hca Healthcare Inc

NYSE:HCA

HCA Rankings

HCA Latest News

HCA Latest SEC Filings

HCA Stock Data

118.85B
156.63M
30.82%
63.17%
1.83%
Medical Care Facilities
Services-general Medical & Surgical Hospitals, Nec
Link
United States
NASHVILLE